Expansion opportunities With recent investments in European and US facilities, BioReliance is expanding its capability to perform biologics safety testing and drug substance/product release testing. This presents upsell potential for broader GLP/GMP testing services, method development, and added characterization services for late-stage and commercial products across new regions.

Regulatory testing demand As a leading GMP and GLP testing provider serving regulatory bodies like FDA and MHRA, BioReliance’s services are critical for pharma and biotech clients aiming to bring therapies to market. This indicates strong cross-sell opportunities into risk mitigation, compliance testing, and regulatory submission support for both emerging and established biopharma companies.

Strategic partnerships The BioReliance portfolio supports end-to-end solutions for complex biologics, suggesting collaboration opportunities with CDMOs, biotech startups, and large pharma seeking integrated testing and qualification services for accelerated development timelines.

Sustainability & innovation Leadership in sustainability showcased by executives speaking at CHEMUK 2026, coupled with ongoing center expansions, signals a value proposition for customers prioritizing responsible sourcing, efficiency improvements, and advanced analytics in testing workflows.

Key personnel leverage Recent leadership appointments in discovery and strategy roles indicate a focus on accelerating innovation and market strategy, which could be leveraged to position new offerings such as conjugation, endpoints, and assay development services to prospective clients seeking cutting-edge solutions.